Cornercap Investment Counsel Inc. Invests $223,000 in Replimune Group, Inc. (NASDAQ:REPL)

Cornercap Investment Counsel Inc. purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 26,493 shares of the company’s stock, valued at approximately $223,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of REPL. Vontobel Holding Ltd. acquired a new position in shares of Replimune Group during the fourth quarter valued at approximately $2,575,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Replimune Group by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,223 shares of the company’s stock valued at $339,000 after purchasing an additional 9,859 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Replimune Group by 352.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,833 shares of the company’s stock valued at $58,000 after purchasing an additional 5,324 shares in the last quarter. Harbor Capital Advisors Inc. boosted its stake in Replimune Group by 6.1% during the 4th quarter. Harbor Capital Advisors Inc. now owns 32,311 shares of the company’s stock worth $272,000 after purchasing an additional 1,844 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in Replimune Group by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 7,837 shares of the company’s stock worth $66,000 after purchasing an additional 1,988 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $7.21 on Thursday. The firm has a 50-day simple moving average of $7.98 and a 200-day simple moving average of $9.62. The company has a current ratio of 12.40, a quick ratio of 12.40 and a debt-to-equity ratio of 0.16. Replimune Group, Inc. has a 52 week low of $5.89 and a 52 week high of $24.81.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Thursday, February 8th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.12. Equities research analysts predict that Replimune Group, Inc. will post -3.28 EPS for the current year.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.